International Consensus on the Use of Tau PET Imaging Agent F-flortaucipir in Alzheimer's Disease

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2022 Jan 3

PMID 34978595

Citations 22

Authors

Mei Tian

A Cahid Civelek

Ignasi Carrio

Yasuyoshi Watanabe

Keon Wook Kang

Koji Murakami

Valentina Garibotto

John O Prior

Henryk Barthel

Rui Zhou

Haifeng Hou

Xiaofeng Dou

Chentao Jin

Chuantao Zuo

Hong Zhang

Affiliations

Soon will be listed here.

Abstract

Purpose: Positron emission tomography (PET) with the first and only tau targeting radiotracer of F-flortaucipir approved by FDA has been increasingly used in depicting tau pathology deposition and distribution in patients with cognitive impairment. The goal of this international consensus is to help nuclear medicine practitioners procedurally perform F-flortaucipir PET imaging.

Method: A multidisciplinary task group formed by experts from various countries discussed and approved the consensus for F-flortaucipir PET imaging in Alzheimer's disease (AD), focusing on clinical scenarios, patient preparation, and administered activities, as well as image acquisition, processing, interpretation, and reporting.

Conclusion: This international consensus and practice guideline will help to promote the standardized use of F-flortaucipir PET in patients with AD. It will become an international standard for this purpose in clinical practice.

Citing Articles

The basics of PET molecular imaging in neurodegenerative disorders with dementia and/or parkinsonism.

Bronte A, Prieto E, Quincoces G, Erro E, Arbizu J Eur Radiol. 2025; .

PMID: 39918781 DOI: 10.1007/s00330-025-11388-5.

Radiopharmaceuticals and their applications in medicine.

Zhang S, Wang X, Gao X, Chen X, Li L, Li G Signal Transduct Target Ther. 2025; 10(1):1.

PMID: 39747850 PMC: 11697352. DOI: 10.1038/s41392-024-02041-6.

Molecular imaging: The bridge from human phenome to personalized precision medicine.

Tian M, Gao Y, Xue C, Jin C, Zhang H Eur J Nucl Med Mol Imaging. 2024; 52(4):1233-1236.

PMID: 39724182 DOI: 10.1007/s00259-024-07048-3.

Head-to-head comparison of tau PET tracers [F]PI-2620 and [F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort.

Tonietto M, Sotolongo-Grau O, Roe-Vellve N, Bullich S, Tartari J, Sanabria A Alzheimers Res Ther. 2024; 16(1):257.

PMID: 39605030 PMC: 11603960. DOI: 10.1186/s13195-024-01622-5.

Thai Guideline for Nuclear Medicine Investigations of Neurocognitive Disorders: Nuclear Medicine Society of Thailand, the Neurological Society of Thailand, and Thai Medical Physicist Society Collaboration.

Kaewchur T, Thientunyakit T, Chamroonrat W, Khiewvan B, Kiatkittikul P, Wongsurawat N Diagnostics (Basel). 2024; 14(22).

PMID: 39594140 PMC: 11592784. DOI: 10.3390/diagnostics14222474.

References

Dubois B, Villain N, Frisoni G, Rabinovici G, Sabbagh M, Cappa S . Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurol. 2021; 20(6):484-496. PMC: 8339877. DOI: 10.1016/S1474-4422(21)00066-1. View

Storandt M, Mintun M, Head D, Morris J . Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol. 2009; 66(12):1476-81. PMC: 2796577. DOI: 10.1001/archneurol.2009.272. View

Ballatore C, Lee V, Trojanowski J . Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci. 2007; 8(9):663-72. DOI: 10.1038/nrn2194. View

Chabrier M, Blurton-Jones M, Agazaryan A, Nerhus J, Martinez-Coria H, LaFerla F . Soluble aβ promotes wild-type tau pathology in vivo. J Neurosci. 2012; 32(48):17345-50. PMC: 3586232. DOI: 10.1523/JNEUROSCI.0172-12.2012. View

Bierer L, Hof P, Purohit D, Carlin L, Schmeidler J, Davis K . Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch Neurol. 1995; 52(1):81-8. DOI: 10.1001/archneur.1995.00540250089017. View

Tian M, He X, Jin C, He X, Wu S, Zhou R . Transpathology: molecular imaging-based pathology. Eur J Nucl Med Mol Imaging. 2021; 48(8):2338-2350. PMC: 8241651. DOI: 10.1007/s00259-021-05234-1. View

Zhu L, Ploessl K, Kung H . PET/SPECT imaging agents for neurodegenerative diseases. Chem Soc Rev. 2014; 43(19):6683-91. PMC: 4159420. DOI: 10.1039/c3cs60430f. View

Chiotis K, Saint-Aubert L, Savitcheva I, Jelic V, Andersen P, Jonasson M . Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm. Eur J Nucl Med Mol Imaging. 2016; 43(9):1686-99. PMC: 4932128. DOI: 10.1007/s00259-016-3363-z. View

Hashimoto H, Kawamura K, Igarashi N, Takei M, Fujishiro T, Aihara Y . Radiosynthesis, photoisomerization, biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology. J Nucl Med. 2014; 55(9):1532-8. DOI: 10.2967/jnumed.114.139550. View

10.

Brendel M, Schonecker S, Hoglinger G, Lindner S, Havla J, Blautzik J . [F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy. Front Aging Neurosci. 2018; 9:440. PMC: 5776329. DOI: 10.3389/fnagi.2017.00440. View

11.

Coakeley S, Cho S, Koshimori Y, Rusjan P, Harris M, Ghadery C . Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. J Cereb Blood Flow Metab. 2017; 37(9):3150-3160. PMC: 5584690. DOI: 10.1177/0271678X16683695. View

12.

Leuzy A, Chiotis K, Lemoine L, Gillberg P, Almkvist O, Rodriguez-Vieitez E . Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry. 2019; 24(8):1112-1134. PMC: 6756230. DOI: 10.1038/s41380-018-0342-8. View

13.

Wolters E, Dodich A, Boccardi M, Corre J, Drzezga A, Hansson O . Clinical validity of increased cortical uptake of [F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework. Eur J Nucl Med Mol Imaging. 2021; 48(7):2097-2109. PMC: 8175307. DOI: 10.1007/s00259-020-05118-w. View

14.

Wang Y, Mandelkow E . Tau in physiology and pathology. Nat Rev Neurosci. 2015; 17(1):5-21. DOI: 10.1038/nrn.2015.1. View

15.

Goedert M, Spillantini M, Jakes R, Rutherford D, Crowther R . Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron. 1989; 3(4):519-26. DOI: 10.1016/0896-6273(89)90210-9. View

16.

Salvado G, Ferreira D, Operto G, Cumplido-Mayoral I, Arenaza-Urquijo E, Cacciaglia R . The protective gene dose effect of the APOE ε2 allele on gray matter volume in cognitively unimpaired individuals. Alzheimers Dement. 2021; 18(7):1383-1395. PMC: 9542211. DOI: 10.1002/alz.12487. View

17.

Reisberg B, Ferris S, de Leon M, Crook T . The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982; 139(9):1136-9. DOI: 10.1176/ajp.139.9.1136. View

18.

Barthel H . First Tau PET Tracer Approved: Toward Accurate In Vivo Diagnosis of Alzheimer Disease. J Nucl Med. 2020; 61(10):1409-1410. DOI: 10.2967/jnumed.120.252411. View

19.

Lowe V, Lundt E, Albertson S, Min H, Fang P, Przybelski S . Tau-positron emission tomography correlates with neuropathology findings. Alzheimers Dement. 2019; 16(3):561-571. PMC: 7067654. DOI: 10.1016/j.jalz.2019.09.079. View

20.

Fragoso Costa P, Santos A, Testanera G . An insight into the EANM technologist committee benchmark document on nuclear medicine technologists' competencies. Eur J Nucl Med Mol Imaging. 2017; 44(9):1604-1606. DOI: 10.1007/s00259-017-3741-1. View